PMID- 22993319
OWN - NLM
STAT- MEDLINE
DCOM- 20130104
LR  - 20120920
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 32
IP  - 9
DP  - 2012 Sep
TI  - Knockdown of receptor-interacting serine/threonine protein kinase-2 (RIPK2) 
      affects EMT-associated gene expression in human hepatoma cells.
PG  - 3775-83
AB  - BACKGROUND: Receptor-interacting serine/threonine protein kinase-2 (RIPK2) has 
      been reported to be an important regulator of tumor proliferation, 
      differentiation and wound repair. We investigated the effects of RIPK2 knockdown 
      in human hepatoma cells on epithelial-to-mesenchymal transition (EMT)-associated 
      gene expression. MATERIALS AND METHODS: HepG2 cells stably expressing RIPK2-shRNA 
      (HepG2-shRIPK2) were generated after puromycin selection. Total RNAs from 
      HepG2-shRIPK2 and from HepG2-shcontrol cells were isolated and PCR-based arrays 
      were performed to compare the 84 EMT-associated gene expressions. RESULTS: We 
      observed that knockdown of RIPK2 down-regulated mRNA expression of jagged 1 
      (JAG1); plasminogen activator inhibitor-1 (PAI1); regulator of G-protein 
      signalling 2, 24 kDa (RGS2); E-cadherin (CDH1); fibroblast growth factor binding 
      protein 1 (FGFBP1); snail homolog 2 (SNAI2); protein tyrosine phosphatase type 
      IVA, member 1 (PTP4A1); keratin 19 (KRT19); vimentin (VIM); and survival of motor 
      neuron protein-interacting protein 1 (SIP1). CONCLUSION: We found that knockdown 
      of RIPK2 down-regulated nuclear factor kappa B (NF-kappaB)-dependent PAI1 and VIM 
      gene expressions. RIPK2 might play an important role in hepatic cell migration. 
      These findings could shed new light on carcinogenesis and on liver regeneration.
FAU - Wu, Shuang
AU  - Wu S
AD  - Department of Medicine and Clinical Oncology, Chiba University, Graduate School 
      of Medicine, Chuo-ku, Chiba, Japan.
FAU - Kanda, Tatsuo
AU  - Kanda T
FAU - Nakamoto, Shingo
AU  - Nakamoto S
FAU - Imazeki, Fumio
AU  - Imazeki F
FAU - Yokosuka, Osamu
AU  - Yokosuka O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (NF-kappa B)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.1 (RIPK2 protein, human)
RN  - EC 2.7.11.1 (Receptor-Interacting Protein Serine-Threonine Kinase 2)
SB  - IM
MH  - Carcinoma, Hepatocellular/enzymology/*genetics/pathology
MH  - Down-Regulation
MH  - Epithelial-Mesenchymal Transition/*genetics
MH  - *Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - Hep G2 Cells
MH  - Humans
MH  - Liver Neoplasms/enzymology/*genetics/pathology
MH  - NF-kappa B/genetics
MH  - RNA, Messenger/biosynthesis/genetics
MH  - Receptor-Interacting Protein Serine-Threonine Kinase 
      2/deficiency/*genetics/metabolism
MH  - Transfection
MH  - Up-Regulation
EDAT- 2012/09/21 06:00
MHDA- 2013/01/05 06:00
CRDT- 2012/09/21 06:00
PHST- 2012/09/21 06:00 [entrez]
PHST- 2012/09/21 06:00 [pubmed]
PHST- 2013/01/05 06:00 [medline]
AID - 32/9/3775 [pii]
PST - ppublish
SO  - Anticancer Res. 2012 Sep;32(9):3775-83.